Mouse only (beta-thalassemic and wild-type C57BL/6 transplant models; immunodeficient mice for human cells)
“The following toxicology studies were conducted to evaluate the safety of human HSCs or mBMCs transduced with BB305 LVV following administration in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Why that species
Beta-thalassemic (Hbbth1/th1) mouse disease model allowed pharmacology and toxicity assessment of transduced syngeneic marrow
“To evaluate the pharmacologic and toxicologic effects of mBMCs transduced with BB305 LVV or mBMCs transduced with HPV569 LVV following IV administration in β-thalassemic mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗
Surrogate molecule
Yes: murine bone marrow cells transduced with clinical BB305 vector (homologous cell product); human CD34+ in immunodeficient mice
“Test Articles • mBMCs transduced with BB305 LVV (Lot No. • mBMCs transduced with HPV569 LVV (Lot No. Control Article mBMCs; mock-transduced”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗
Species: general tox
Mouse only (β-thalassemic and wild-type C57BL/6 primary/secondary transplant studies)
“In vivo studies were also conducted to assess the activity and safety of mBMCs transduced with BB305 following primary and secondary transplantation in β-thalassemic and wild-type C57BL/6 mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Species: DART
Not conducted (no adverse findings in mouse reproductive tissues)
“Per the applicant, developmental and reproductive toxicology studies were not conducted because there were no adverse findings in the male and female reproductive tissues of mice administered mBMCs transduced with BB305 LVV”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Species: carcinogenicity
Not conducted (acceptable based on product type)
“No traditional carcinogenicity studies were conducted with lovo-cel which is acceptable based on the product type.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Surrogate used in
Yes: murine bone marrow cells as surrogate cell product; SCD transgenic mouse POC used a related βA-T87Q vector
“In vivo POC studies were also conducted using transgenic mouse models of SCD, where murine bone marrow cells (mBMCs) were transduced with the βA-T87Q LVV, a related vector encoding the same transgene, and showed expression of βA-T87Q and correction of the sickling phenotype through 3 months post-transplantation.”
✓ VerifiedFDA summary basis for approval, p. 11Source ↗